NASDAQ:NLSP - Nasdaq - CH1384053976 - Common Stock - Currency: USD
1.84
+0.02 (+1.1%)
The current stock price of NLSP is 1.84 USD. In the past month the price decreased by -7.07%. In the past year, price decreased by -87.14%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 70.82 | 873.97B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 28.42 | 402.40B | ||
JNJ | JOHNSON & JOHNSON | 16.52 | 397.31B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 21.05 | 236.34B | ||
MRK | MERCK & CO. INC. | 12.07 | 233.36B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.73 | 215.38B | ||
PFE | PFIZER INC | 8.5 | 149.78B | ||
SNY | SANOFI-ADR | 13.65 | 136.57B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 52.3 | 120.92B | ||
GSK | GSK PLC-SPON ADR | 8.01 | 76.71B | ||
ZTS | ZOETIS INC | 28.25 | 75.45B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.75 | 45.68B |
NLS Pharmaceutics AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Zurich, Zuerich and currently employs 3 full-time employees. The company went IPO on 2021-01-29. NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
NLS PHARMACEUTICS LTD
The Circle 6
Zurich ZUERICH CH-6370 CH
CEO: Alexander Zwyer
Employees: 7
Company Website: https://nlspharma.com/
Investor Relations: http://nlspharma.com/investors/sec-filings/
Phone: 41445122150
The current stock price of NLSP is 1.84 USD. The price increased by 1.1% in the last trading session.
The exchange symbol of NLS PHARMACEUTICS LTD is NLSP and it is listed on the Nasdaq exchange.
NLSP stock is listed on the Nasdaq exchange.
NLS PHARMACEUTICS LTD (NLSP) has a market capitalization of 3.64M USD. This makes NLSP a Nano Cap stock.
NLS PHARMACEUTICS LTD (NLSP) currently has 7 employees.
NLS PHARMACEUTICS LTD (NLSP) has a support level at 1.77 and a resistance level at 2.04. Check the full technical report for a detailed analysis of NLSP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NLSP does not pay a dividend.
NLS PHARMACEUTICS LTD (NLSP) will report earnings on 2022-12-13, before the market open.
NLS PHARMACEUTICS LTD (NLSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.72).
The outstanding short interest for NLS PHARMACEUTICS LTD (NLSP) is 9.51% of its float. Check the ownership tab for more information on the NLSP short interest.
ChartMill assigns a fundamental rating of 1 / 10 to NLSP. Both the profitability and financial health of NLSP have multiple concerns.
Over the last trailing twelve months NLSP reported a non-GAAP Earnings per Share(EPS) of -6.72. The EPS increased by 19.12% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -552.58% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to NLSP. The Buy consensus is the average rating of analysts ratings from 6 analysts.